TargetMol

LILRB1/CD85j/ILT2 Protein, Rhesus macaque, Recombinant (aa 17-456, His)

Product Code:
 
TAR-TMPJ-00621
Product Group:
 
Recombinant Proteins
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1

Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TMPJ-00621-10ug10ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPJ-00621-1mg1mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPJ-00621-500ug500ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPJ-00621-50ug50ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Show All

Further Information

Bioactivity:
LILRB1, also known as CD85j and ILT2, is a transmembrane glycoprotein in the LILR immunoregulatory protein family. LILRB1 is expressed on NK cells that have expanded in response to acute HCMV infection. LILRB1 exhibits considerable diversity in the population, and polymorphisms in the LILRB1 gene have been associated with susceptibility to rheumatoid arthritis and weakly associated with HCMV disease in a subset of patients with HIV. The regulation of phagocytosis by macrophages is an additional key role of LILRB1 signaling. LILRB1 recognizes a wide variety of HLA haplotypes due to its interaction with the invariant β2M subunit of MHC class I, which suggests that this signaling axis is relevant across diverse patient populations.
Molecular Weight:
60-85 kDa (reducing condition)
Purity:
98%